Acute myocardial ischemia without necrosis

Article written and reviewed by Dr Luca Moretti

Acute myocardial ischemia without necrosis is a condition in which the myocardium undergoes an acute reduction in oxygen supply sufficient to cause symptoms and sometimes electrocardiographic changes, but not cellular injury sufficient to produce the troponin pattern required for a diagnosis of myocardial infarction. In the setting of an atherothrombotic acute coronary syndrome, this phenotype primarily corresponds to modern unstable angina.
The definition has become more selective with the widespread use of high-sensitivity cardiac troponins. Many patients who would previously have been classified as having unstable angina with less sensitive biomarkers now show small dynamic increases in troponin and are correctly reclassified as NSTEMI. Consequently, unstable angina accounts for a smaller proportion of NSTE-ACS and requires particular care to avoid both overdiagnosis and false reassurance.

The absence of necrosis does not imply a benign condition. A transient coronary thrombus, plaque erosion, or a critical stenosis with recurrent ischemia may initially produce no diagnostic troponin release yet rapidly progress to infarction, arrhythmia, or hemodynamic instability. Risk must therefore be defined by integrating clinical findings, serial ECGs, biomarkers, the probability of coronary artery disease, and imaging.
Unstable angina must also be distinguished from ordinary chronic angina. New pain at rest, a recent increase in the frequency or duration of episodes, a lower exertional threshold, or a new ischemic pattern suggest instability; however, no single feature of the history is sufficiently specific, and the term “crescendo” must be interpreted within the full clinical picture.

The expression “ischemia without necrosis” may itself encompass mechanisms other than atherothrombosis, including epicardial vasospasm, microvascular dysfunction, or an acute supply-demand imbalance; these phenotypes must not automatically be treated as plaque rupture. Whenever possible, the final diagnosis should describe the mechanism, anatomy, and risk rather than merely assigning a syndromic label.

Etiology, pathogenesis, and pathophysiology

In the atherothrombotic form, the substrate is a coronary plaque that develops a surface complication. Plaque rupture, endothelial erosion, and, less commonly, an eruptive calcified nodule expose thrombogenic material and activate platelets and coagulation. If the thrombus remains nonocclusive, fragments, or is rapidly lysed, flow may decrease intermittently without causing biomarker-detectable acute myocardial injury.
Rupture brings blood into contact with the tissue factor-rich necrotic core. Erosion, by contrast, may cause thrombosis over an apparently intact fibrous cap with loss of its endothelial lining; these mechanisms are histologically distinct but may produce overlapping clinical phenotypes.

Platelet activation includes adhesion mediated by von Willebrand factor and collagen, release of ADP and thromboxane A2, and activation of the GPIIb/IIIa receptor. Thrombin converts fibrinogen to fibrin and amplifies platelet activation. The balance among thrombus propagation, residual flow, and endogenous fibrinolysis determines the severity and duration of ischemia.
Thrombosis may be dynamic. Repeated episodes of thrombus formation and dissolution cause intermittent symptoms and may produce distal microembolization. If the amount of injury remains below the diagnostic biomarker threshold, the patient may continue to be classified as having unstable angina; if a rise and/or fall in troponin appears with evidence of ischemia, the condition becomes NSTEMI.

Epicardial vasospasm may cause severe, transient ischemia even in an artery without a significant fixed stenosis. Intense smooth-muscle contraction may almost completely narrow the lumen and cause transient ST-segment elevation or depression. Necrosis may not occur if flow is restored rapidly.
Microvascular dysfunction may cause ischemia without epicardial obstruction and may have a chronic or episodic phenotype. In the acute setting, microvascular spasm and markedly impaired coronary flow reserve may mimic NSTE-ACS. Its characterization nevertheless requires a diagnostic pathway different from that used for obstructive coronary artery disease.

An imbalance between myocardial oxygen demand and supply may result from tachyarrhythmia, severe hypertension, anemia, hypoxemia, or hypotension. If the imbalance causes acute myocardial injury with evidence of ischemia, it is termed secondary myocardial infarction; if no documentable acute myocardial injury occurs, it remains an episode of ischemia without infarction. This distinction matters because intensive antithrombotic therapy is not automatically indicated in the absence of atherothrombosis.
At the myocardial level, reduced oxygen supply causes a rapid shift to anaerobic metabolism, accumulation of lactate and protons, ATP depletion, and impaired diastolic function. Diastolic dysfunction may precede overt systolic abnormalities and contribute to dyspnea or a transient rise in filling pressures.

Ischemia alters ionic gradients and repolarization, producing ST-segment depression or elevation and T-wave inversion according to location, transmural extent, and vector direction. These changes may disappear rapidly when flow normalizes, which is why a normal ECG recorded when pain is absent does not exclude the event.
The duration of ischemia required to produce necrosis is not fixed. It depends on the severity of the flow deficit, metabolic demand, temperature, collateral circulation, and tissue vulnerability. Ischemia without necrosis is therefore biologically continuous with infarction but clinically distinguished by the presence or absence of documentable myocardial injury.

Clinical manifestations

The classic presentation is oppressive chest pain or discomfort occurring at rest or with less exertion than previously, lasting several minutes, and possibly recurring. Radiation to the arms, shoulders, neck, jaw, or epigastrium, together with dyspnea, sweating, and nausea, increases compatibility with ischemia but is not specific.
A new pattern of severe angina or a clear crescendo over the preceding weeks or days may represent instability. The older Braunwald clinical classification had major historical value, but modern management relies more heavily on the ECG, high-sensitivity troponin, risk scores, and anatomy.

In older adults, women, people with diabetes, and patients with kidney disease, dyspnea, fatigue, nausea, or syncope may dominate the presentation. The term “atypical” is now less useful because it may unjustifiably lower the perceived probability of ischemia in presentations that genuinely occur.
Physical examination may be normal. Hypotension, signs of heart failure, a new murmur, arrhythmia, or hypoperfusion instead indicate a high-risk condition and should accelerate evaluation. Examination must simultaneously seek life-threatening alternative diagnoses, including aortic dissection, pulmonary embolism, and pneumothorax.

Persistent or recurrent pain despite initial therapy is a sign of instability. In particular, refractory ischemia, extensive dynamic ECG changes, ventricular arrhythmias, or shock require an urgent invasive strategy regardless of an initially normal troponin.

Investigations, diagnosis, and risk stratification

A 12-lead ECG should be obtained promptly and repeated if symptoms persist or recur. Dynamic ST-segment depression and deep or dynamic T-wave inversions increase the probability of ischemia. A normal ECG does not exclude NSTE-ACS, particularly when recorded after pain has resolved.
High-sensitivity cardiac troponin should be measured using validated serial algorithms. A diagnosis of infarction requires acute myocardial injury, documented by a rise and/or fall with at least one value above the sex-specific 99th percentile, together with evidence of ischemia. If this criterion is not met, the patient must not be labeled as having NSTEMI on the basis of symptoms alone.

0/1-hour or 0/2-hour strategies permit rapid rule-out or rule-in in many patients, but an observation zone remains in which further samples and evaluation are required. Time from symptom onset, kidney function, and chronically elevated values must be considered in interpretation.
Unstable angina is therefore a clinical diagnosis that presupposes plausible acute ischemia without demonstrated acute myocardial injury at the time of evaluation. A negative troponin in a patient with nonischemic pain does not define unstable angina. The risk of overdiagnosis is particularly high when the term is used as a catch-all for any chest pain in a patient with risk factors.

Echocardiography may identify new regional wall-motion abnormalities, global dysfunction, or alternative diagnoses. A transient regional abnormality during ischemia supports a coronary mechanism, but a normal echocardiogram does not exclude brief episodes that have already resolved.
CCTA may be useful in selected low-to-intermediate-risk patients in whom the diagnosis remains uncertain and there is no immediate indication for coronary angiography. Its strong ability to exclude obstructive coronary disease reduces unnecessary invasive procedures, but it is inappropriate when the patient is unstable or the probability of intervention is high.

Invasive coronary angiography defines anatomy and permits revascularization. In intermediate- or high-risk NSTE-ACS, the 2025 ACC/AHA guidelines recommend an invasive approach during hospitalization with the intent to proceed to revascularization when appropriate. In low-risk patients, a routine or selective invasive strategy with further stratification is reasonable.
GRACE and other scores may complement assessment but do not replace clinical judgment. Hemodynamic instability, malignant arrhythmias, persistent ischemia, or mechanical complications take priority over an isolated numerical calculation.

When the coronary arteries are nonobstructive, the diagnosis must be reconsidered. Vasospasm, microvascular dysfunction, spontaneous dissection, coronary embolism, and noncoronary causes may explain the presentation. MINOCA now denotes a working diagnosis of myocardial injury with nonobstructive coronary arteries and does not require that infarction already be confirmed.

Antithrombotic and anti-ischemic treatment and the invasive strategy

Initial management includes monitoring, intravenous access, serial ECGs, and prompt risk assessment. Oxygen should not be given routinely to normoxemic patients; it is indicated when hypoxemia or respiratory compromise is present. This distinction avoids automatic use of interventions without proven benefit.
Aspirin should be administered promptly in suspected ACS in the absence of contraindications. It irreversibly inhibits platelet COX-1 and reduces thromboxane production. After loading, it is continued at a low dose according to the overall antithrombotic strategy.

The choice and timing of a P2Y12 inhibitor depend on the invasive strategy and bleeding risk. In patients with NSTE-ACS undergoing PCI, ticagrelor or prasugrel is generally preferred to clopidogrel when appropriate. Indiscriminate pretreatment before the anatomy is known is not a universal rule and may increase bleeding or complicate a subsequent CABG.
The 2025 ACC/AHA guidelines state that, if an invasive strategy is planned but angiography will occur more than 24 hours later, upstream treatment with clopidogrel or ticagrelor may be considered; this differs from stating that every patient with chest pain and a negative troponin should receive immediate DAPT.

Parenteral anticoagulation is used in NSTE-ACS according to the strategy and timing, with unfractionated heparin, enoxaparin, or fondaparinux in appropriate settings. The choice must consider kidney function, bleeding risk, and the planned intervention. If the final diagnosis is not atherothrombotic, the need for anticoagulation must be reassessed.
Nitrates reduce preload and may relieve ischemia and pain, but they have not demonstrated a direct prognostic benefit and are contraindicated in hypotension, suspected right ventricular infarction, or recent use of phosphodiesterase-5 inhibitors. Response to a nitrate does not diagnose ischemia.

Beta-blockers reduce heart rate and oxygen consumption and may be useful in the absence of acute heart failure, shock, severe bradycardia, or other contraindications. They may be unsuitable in pure vasospasm, particularly nonselective beta-blockade; the suspected mechanism must therefore inform the choice.
Revascularization is indicated when anatomy and physiology demonstrate appropriate culprit lesions. PCI and CABG are selected according to the presentation, anatomical complexity, diabetes, ventricular function, and the feasibility of complete revascularization. Treatment does not end with the procedure because atherosclerosis remains a systemic process.

Lipid-lowering therapy should be intensified early. The 2025 ACS guidelines recommend a high-intensity statin for all patients with ACS and permit simultaneous initiation of ezetimibe; appropriate nonstatin agents should be added in patients who remain above target on maximal therapy. The 2026 dyslipidemia guidelines specify particularly low targets in patients with very-high-risk ASCVD.
The standard duration of DAPT after ACS is approximately 12 months in patients without high bleeding risk, with abbreviated or de-escalation strategies in selected patients. The final regimen depends on the actual diagnosis of ACS, invasive treatment, and bleeding risk.

If vasospasm is the cause, calcium-channel blockers are the cornerstone of treatment and nitrates may be added. If microvascular dysfunction is identified, treatment should be guided by the endotype. The initial classification of “ischemia without necrosis” must therefore not prevent subsequent etiologic precision.

Complications, secondary prevention, and prognosis

The principal complication is progression to NSTEMI or STEMI. An initially nonocclusive thrombus may propagate, endogenous lysis may fail, or a plaque may undergo further destabilization. Clinical surveillance and timely access to revascularization in at-risk patients are specifically intended to prevent this transition.
Acute ischemia may cause ventricular tachycardia or ventricular fibrillation even before extensive necrosis develops. Dispersion of repolarization, slowed conduction, and sympathetic activation make the myocardium electrically unstable.

Extensive ischemia may cause transient ventricular dysfunction, functional mitral regurgitation, and pulmonary edema. The onset of heart failure during NSTE-ACS is a high-risk sign and changes the priority of the invasive strategy.
After discharge, risk depends more on the overall atherosclerotic burden and comorbidities than on the absence of necrosis during the index episode. A patient with unstable angina and severe left main stenosis may have greater anatomical risk than a patient with a small NSTEMI caused by a distal lesion.

Secondary prevention should include smoking cessation, blood-pressure and metabolic control, physical activity, rehabilitation when indicated, and intensive reduction of atherogenic lipoproteins. The absence of necrosis during the first episode does not justify less aggressive preventive treatment when clinically significant atherosclerotic coronary disease is documented.

Unstable angina in the high-sensitivity troponin era

The transition from CK-MB and conventional troponins to high-sensitivity cardiac troponins has changed the taxonomy of NSTE-ACS. Greater sensitivity identifies small acute ischemic myocardial injuries that previously remained undetected, moving patients from the unstable-angina category to NSTEMI. The declining incidence of UA in contemporary registries is therefore partly a diagnostic effect, not necessarily the biological disappearance of ischemia without necrosis.
High-sensitivity troponin assays measure detectable concentrations even in many healthy people. The diagnostic issue is not mere detectability but comparison with the assay's sex-specific 99th percentile and the presence of change over time. Chronically elevated values are common in CKD, structural heart disease, and older people and require interpretation of the delta.

A patient with ischemic pain and troponin values consistently below the sex-specific 99th percentile may have UA, but the diagnosis must be robust. There must be a high probability of acute ischemia based on the clinical pattern, ECG, imaging, or anatomy. Using UA as the default diagnosis for unexplained chest pain reduces precision and may expose the patient to unnecessary antithrombotic therapy.
Sampling time is crucial. A sample obtained only minutes after onset may be negative even in an evolving infarction. Accelerated algorithms are validated at precise intervals and require a second sample when the first cannot provide reliable rule-out.

Traditional point-of-care tests and different laboratory assays are not interchangeable. Each platform has its own cutoffs, precision, and delta. Applying a threshold derived from another test may lead to misclassification.
The distinction between myocardial injury and MI is fundamental. If troponin is elevated but there is no evidence of ischemia, the patient has acute or chronic myocardial injury, not automatically NSTEMI. If ischemia results from a supply-demand imbalance without a primary acute coronary disorder, it may be secondary myocardial infarction, and the strategy should address the cause.

Contemporary UA tends to occur in patients with strongly suggestive symptoms and important coronary disease but negative biomarkers. Some studies show a lower average risk than in troponin-positive NSTEMI, but subgroups with severe anatomy remain at high risk.
The concept of “absent necrosis” is limited by the available sensitivity. No biomarker can prove that not a single cardiomyocyte has died; clinically, it means that acute myocardial injury sufficient to exceed diagnostic criteria has not been documented. The distinction is operational and prognostic, not an absolute histologic statement.

Electrocardiography, imaging, and advanced differential diagnosis

ST-segment depression during pain is one of the most important findings in NSTE-ACS. Its depth, the number of leads involved, and its dynamic nature carry prognostic significance. Diffuse depression associated with elevation in aVR may indicate extensive subendocardial ischemia, but it is not specific for left main disease and must be interpreted in the clinical context.
Deep, symmetric T-wave inversions in the anterior precordial leads after pain has resolved may suggest Wellens syndrome, which is associated with critical proximal left anterior descending stenosis. Exercise testing may be dangerous in this setting, and invasive evaluation is generally indicated.

The de Winter pattern, with upsloping ST-segment depression and tall, symmetric T waves, may indicate acute LAD occlusion and requires management as a high-risk coronary occlusion even without classic persistent ST-segment elevation.
Recording posterior leads V7-V9 may identify posterior infarction when anterior ST depression raises suspicion. Right-sided leads are useful when right ventricular involvement is suspected; these measures prevent a true occlusion with a nonstandard pattern from being incorrectly classified as NSTE-ACS.

Bedside echocardiography may identify regional abnormalities during pain, but sensitivity depends on their extent and duration. The absence of a wall-motion abnormality does not exclude brief ischemia. Its greatest value is often rapid assessment of function, valves, complications, and alternative diagnoses.
CCTA is particularly useful when the probability of ACS is intermediate and troponin and ECG are nondiagnostic. A CCTA showing no significant plaque markedly reduces the probability of atherothrombotic ACS; however, heavy calcification, tachycardia, or previous stents may limit image quality.

Cardiac magnetic resonance can distinguish infarction, myocarditis, and Takotsubo syndrome when the presentation remains uncertain after angiography. In true unstable angina, by definition, it should not show an infarction-pattern area of necrosis; acute ischemic LGE suggests that myocardial injury has occurred.
The differential diagnosis of chest pain must remain broad. Aortic dissection may be worsened by antithrombotic drugs; pulmonary embolism may increase troponin and cause ECG changes; myocarditis may mimic ACS. Discordant clinical signs must be recognized before aggressive antithrombotic therapy.

Spontaneous coronary artery dissection is an important cause of ACS, particularly in younger women, and is not plaque-mediated atherothrombosis. Instrumentation and PCI may be more hazardous, and stable patients are often managed conservatively. Labeling every NSTE-ACS as atherosclerotic may therefore lead to inappropriate choices.
Coronary embolism may arise from atrial fibrillation, endocarditis, prosthetic valves, or intracardiac thrombi. In the absence of significant atherosclerosis, identifying the mechanism changes antithrombotic therapy and prevention.

Antithrombotic therapy: principles, drug selection, and bleeding risk

The benefit of antithrombotic therapy depends on the probability that the syndrome is truly atherothrombotic. In a patient with high-probability UA, aspirin and anticoagulation reduce thrombus propagation; in noncardiac pain they merely create a bleeding risk. Diagnostic precision is therefore a component of treatment safety.
A loading dose of aspirin is given to achieve rapid platelet inhibition. Alternative strategies are required in patients with true allergy or severe intolerance, and desensitization may be considered in specialist settings when aspirin is strongly indicated.

Among P2Y12 inhibitors, prasugrel must not be administered before the anatomy is known in NSTE-ACS and is contraindicated in patients with previous stroke or TIA. Ticagrelor has a rapid onset and requires no metabolic activation, but it may cause dyspnea and bradyarrhythmias and has drug interactions.
Clopidogrel remains important when bleeding risk, the need for oral anticoagulation, age, availability, or contraindications make more potent agents unsuitable. The choice is therefore not an absolute hierarchy but an individualized balance.

Anticoagulation in NSTE-ACS prevents fibrin formation and thrombus extension. Unfractionated heparin is preferred in many patients scheduled for early PCI because of its short half-life and reversibility; fondaparinux reduces bleeding with more conservative strategies but requires additional UFH at the time of PCI to prevent catheter thrombosis.
Kidney function affects enoxaparin and fondaparinux. In advanced CKD, UFH may be more readily titrated. Kidney failure simultaneously increases ischemic and bleeding risk, making avoidance of overdosing particularly important.

GPIIb/IIIa inhibitors are no longer used routinely upstream. They may have a bail-out role during PCI in the presence of a large thrombus burden, no-reflow, or complications, but bleeding risk limits generalized use.
Bleeding risk should be assessed from the history of bleeding, hemoglobin, platelet count, kidney function, age, malignancy, and the need for anticoagulation. Scores such as ARC-HBR help formalize risk after PCI and guide the duration of DAPT.

Radial access reduces bleeding and vascular complications and is preferred to femoral access in contemporary ACS guidelines when feasible; this illustrates that reducing bleeding risk depends on more than medication alone.
In patients requiring chronic anticoagulation, such as those with atrial fibrillation, prolonged triple therapy greatly increases bleeding. Modern strategies shorten aspirin treatment after PCI and continue an anticoagulant plus clopidogrel for a risk-adjusted period.

Invasive strategy, revascularization, and special scenarios

The invasive strategy should be proportionate to risk. Hemodynamic instability, recurrent ischemia despite treatment, life-threatening arrhythmias, or associated heart failure require urgent evaluation. In stable patients at intermediate-to-high risk, angiography during hospitalization defines the anatomy and permits treatment of significant lesions.
Timing within 24 hours, rather than within a broader window, has primarily been studied in high-risk NSTE-ACS. The benefit of a very early approach is clearest in high-risk patients, whereas not every troponin-negative patient requires immediate overnight angiography.

An intermediate stenosis should not automatically be stented on visual impression alone. In stable patients without an obvious culprit, FFR or iFR may clarify significance. During the acute phase, culprit-vessel physiology may be affected by the microcirculation and requires expert interpretation.
Intravascular imaging with OCT can identify rupture, erosion, thrombus, and dissection and may clarify the mechanism when angiography is ambiguous. IVUS is useful for sizing, calcium assessment, and stent optimization. The 2025 guidelines recommend intravascular imaging to guide PCI in complex lesions during ACS.

In left main or complex multivessel disease, CABG may be preferable to PCI. The presence of UA does not negate the general principles governing the choice of revascularization; the team must balance ischemic urgency against the optimal anatomical strategy.
In patients with diabetes, multivessel disease, and complex anatomy, CABG often provides better long-term protection than PCI; nevertheless, comorbidities, frailty, and technical feasibility must be considered.

ACS is uncommon during pregnancy but is relatively more likely to result from SCAD or other nonatherosclerotic mechanisms. Radiation and medications require multidisciplinary management, but maternal health and necessary revascularization remain the priorities.
In older patients, both ischemic and bleeding risks are high. Frailty, cognitive function, life expectancy, and the patient's goals must supplement risk scores. Advanced age alone justifies neither indiscriminate invasive treatment nor its automatic exclusion.

In patients with cancer, thrombocytopenia, bleeding risk, and interactions modify antithrombotic therapy. Some antineoplastic agents may also induce vasospasm or accelerate atherosclerosis. Management requires cardio-oncology input when available.
After discharge, the patient should receive a specific final diagnosis. “Chest pain” or “unstable angina” without a description of known anatomy makes it difficult to establish DAPT duration, the intensity of lipid lowering, and follow-up. A good discharge summary is part of secondary prevention.

Risk scores, clinical observation, and decision pathways

Risk assessment in NSTE-ACS must not be confused with ruling out infarction. A troponin algorithm may determine that MI is unlikely, but it does not automatically establish whether the patient has unstable angina, aortic dissection, or pulmonary embolism. A clinical diagnosis remains necessary after biomarker assessment.
The GRACE score uses age, heart rate, blood pressure, creatinine, cardiac arrest, ST deviation, biomarkers, and Killip class to estimate mortality. It is one of the most extensively validated ACS tools and may help identify patients who benefit from an earlier invasive strategy.

The TIMI risk score is simpler but less granular. It includes age, risk factors, known coronary disease, aspirin use, anginal episodes, ST deviation, and biomarkers. It retains historical and practical value, but contemporary management integrates hs-cTn and more sophisticated imaging.
Scores must not override very-high-risk features. Shock, refractory pain, ventricular arrhythmias, pulmonary edema, or mechanical instability require an urgent response even if a numerical calculation has not been completed.

In low-risk patients, chest-pain-unit and short-observation protocols may reduce unnecessary admissions. Serial ECGs, troponin, and, when appropriate, CCTA allow a safe decision more rapidly than prolonged admissions with untargeted testing.
Discharge after rule-out nevertheless requires clear instructions about warning signs and a follow-up plan if the probability of chronic coronary disease remains significant. Ruling out MI is not a final diagnosis of the pain.

The HEART score is widely used in emergency departments for chest-pain stratification, but its value depends on the context and the troponin assay used. Pathways incorporating hs-cTn have partly superseded the isolated use of historical scores.
Assessment is more complex in a patient with previous CABG: saphenous vein grafts may develop atherothrombosis, the baseline ECG may be abnormal, and CCTA quality may vary. A lower threshold for invasive imaging may be appropriate when symptoms are convincing.

After recent PCI, chest pain may result from stent thrombosis, less commonly early restenosis, dissection, spasm, or a noncardiac cause. Stent thrombosis is an emergency and should be suspected particularly after premature discontinuation of DAPT.
In patients with recurrent pain and a dynamic ECG but repeatedly negative hs-cTn, the probability of UA increases. If anatomy is unknown, the choice between an invasive strategy and CCTA depends on risk; if a critical stenosis is known, revascularization may be indicated even without positive biomarkers.

Diabetes and CKD increase risk and make some symptoms and biomarkers less specific. An algorithm must therefore be applied carefully, avoiding both excessive hospitalization and discharge based on a superficial reading of troponin.
Advanced age increases the prevalence of chronically elevated hs-cTn. In these patients, the delta and comparison with previous values may be more informative than a single result, but the absence of an increase does not exclude ischemia without necrosis.

Anti-ischemic drugs, post-ACS therapy, and prevention of recurrence

Morphine may relieve severe pain but is not a routine first-line anti-ischemic agent. It may delay absorption of P2Y12 inhibitors and mask symptoms, as well as cause hypotension. It is reserved for refractory pain in selected scenarios.
Sublingual nitrates may be used rapidly for pain if blood pressure and the clinical setting permit. Response does not distinguish ischemic from esophageal pain because both may improve. Using nitrate response diagnostically is therefore incorrect.

Calcium-channel blockers may be useful when beta-blockers are contraindicated or in vasospasm. Nondihydropyridines should be avoided in severe systolic dysfunction because they depress contractility.
Blood-pressure management should avoid extremes. Severe hypertension increases demand and may precipitate ischemia, whereas an excessive reduction impairs coronary perfusion. Vasodilators are titrated according to hemodynamics, not to reach an outpatient target rapidly.

High-intensity statin therapy should be started or confirmed during hospitalization. An early lipid profile allows estimation of baseline LDL before the acute phase and treatment alter it and facilitates planning of combination therapy.
Early ezetimibe may be considered when the target is unlikely to be reached with a statin alone. In patients already receiving maximal treatment whose LDL remains above threshold, PCSK9 inhibitors or other agents may be introduced according to guidelines and access.

After the acute phase, smoking, blood pressure, diabetes, activity, and weight must be addressed. Cardiac rehabilitation provides an ideal setting in which to integrate these components and verify adherence to DAPT.
DAPT duration is adjusted according to ischemic and bleeding risks. Short-DAPT strategies followed by P2Y12 monotherapy may reduce bleeding in selected patients after PCI, whereas patients at high ischemic risk may benefit from longer therapy.

In patients with previous gastrointestinal bleeding or high risk, a proton-pump inhibitor reduces GI risk during DAPT. The combination of omeprazole and clopidogrel has raised concern about CYP2C19 interactions; in practice, a PPI with less interaction may be preferred when appropriate.
After ACS, smoking cessation provides a benefit comparable to that of many drug therapies. Dependence should be treated with counseling and pharmacotherapy, not merely admonitions.

Physical activity is resumed progressively after stabilization. A patient with revascularized UA and normal function may rapidly return to a high level, whereas residual ischemia or reduced LVEF requires exercise assessment and rehabilitation.
Prevention of recurrence also includes treatment of sleep apnea, depression, and psychosocial factors when present; these influence adherence and sympathetic activity, although they do not replace atherosclerosis-directed therapies.

Nonatherothrombotic mechanisms and etiologic diagnosis after the acute phase

Epicardial vasospasm may present with pain at rest, often nocturnal, and transient ST-segment changes. If the patient presents after resolution, both ECG and troponin may be normal. Diagnosis may require acetylcholine provocation testing in a specialist setting.
First-line treatment for vasospasm is a calcium-channel blocker; nitrates may be added. Intensive long-term antithrombotic therapy is not automatically required in the absence of atherosclerosis or another indication.

Microvascular dysfunction may cause ischemic episodes without epicardial stenoses. If a patient has recurrent symptoms after nonobstructive angiography, assessment of CFR, microvascular resistance, and vasoreactivity may identify a treatable endotype.
SCAD may be subtle on angiography, especially when it appears as a long, smooth stenosis. Intravascular imaging may help but carries a risk of extending the dissection; diagnosis should be entrusted to experienced operators. Spontaneous healing is common in stable patients, and conservative management is often preferred.

Coronary embolism should be suspected in the presence of atrial fibrillation, valvular disease, intracardiac thrombi, endocarditis, or a hypercoagulable state. Prevention of recurrence depends on the embolic source and may require anticoagulation instead of prolonged DAPT.
Ischemia caused by severe anemia or hypoxemia requires correction of the cause. Transfusion, oxygenation, and bleeding control may be more important than PCI if no culprit lesion exists. The transfusion threshold depends on severity, symptoms, and the ischemic presentation.

Sustained tachyarrhythmia shortens diastole and increases oxygen consumption. Rate or rhythm control may resolve ischemia if coronary disease is not critical. A dynamic rise in troponin documents acute myocardial injury; a diagnosis of secondary myocardial infarction also requires evidence of ischemia caused by a supply-demand imbalance.
Severe hypertension increases wall stress and demand. Controlled blood-pressure reduction may resolve symptoms, but an excessive fall may worsen coronary perfusion. Treatment must be titrated with monitoring.

Cocaine-associated ischemia combines vasoconstriction, tachycardia, hypertension, and platelet activation. Management includes benzodiazepines, nitrates, and treatment of complications; purely selective beta-blockers have historically been avoided during the acute phase, whereas the role of agents with combined alpha/beta activity is more nuanced.
Other sympathomimetics, including amphetamines, may cause similar mechanisms. The substance-use history should be obtained without judgment because recognition changes treatment and prevention.

Takotsubo syndrome may mimic NSTE-ACS with pain, ECG changes, and a modest troponin elevation. Angiography excludes a culprit lesion, and imaging shows a pattern of dysfunction not confined to one coronary territory. It must not be confused with ischemia without necrosis because a specific acute cardiomyopathy is present.
Myocarditis may cause pain, ST-T changes, and troponin elevation. CMR showing edema and nonischemic LGE helps distinguish it. Antithrombotic drugs and revascularization do not treat the inflammatory mechanism.

The general principle is that the initial syndromic label should be replaced by an etiologic diagnosis as soon as the data permit; this reduces unnecessary medication and focuses attention on genuinely relevant prevention.

Prognosis and follow-up after unstable angina

Patients with contemporary unstable angina have a lower average risk than those with troponin-positive NSTEMI, but risk is heterogeneous. Severe anatomy, diabetes, CKD, ST changes, and previous events may identify a high-risk subgroup despite negative biomarkers.
Prognosis depends heavily on the presence and extent of anatomical coronary artery disease. A patient with ischemic pain and plaque-free coronary arteries follows a different pathway from one with severe multivessel disease who has not yet developed necrosis.

After revascularization, recurrent symptoms require differentiation among restenosis, thrombosis, progression, spasm, and CMD. Automatically repeating the same treatment without redefining the mechanism may lead to numerous unnecessary procedures.
Post-event lipid assessment should be scheduled within weeks to verify attainment of the target. If LDL remains elevated, intensification should not be deferred until an annual visit.

Blood pressure must be controlled without causing hypotension. In patients with exertional angina, an excessive blood-pressure response during exercise may lower the ischemic threshold and benefit from appropriate therapy.
Cardiac rehabilitation is indicated after ACS and revascularization and improves fitness, adherence, and risk-factor management. Unstable angina without infarction is not a reason to exclude a clinically stable patient.

Return to normal activity should be proportionate to risk. It may be rapid after uncomplicated PCI with preserved function; multivessel disease, heart failure, or CABG requires a more structured pathway.
Psychological prognosis is relevant. Some patients become hypervigilant about every chest sensation, whereas others minimize new symptoms. Education and a written plan for warning signs reduce both extremes.

Secondary prevention is permanent. The absence of necrosis in the index episode does not make atherosclerotic disease less real; if a clinically significant plaque is documented, the risk of future events remains high.
The ultimate goal of the pathway is to prevent a reversible episode from becoming the prelude to infarction; ischemia without necrosis is clinically important precisely because it represents a window in which the myocardium remains preserved.

Pathobiology of the culprit plaque and the meaning of absent necrosis

The absence of a troponin increase does not necessarily imply the absence of atherothrombosis. Plaque rupture or erosion may generate a transient or nonocclusive thrombus that reduces flow without producing enough necrosis to exceed the analytical and biological threshold for infarction. Endogenous fibrinolysis, thrombus fragmentation, vasomotion, and collateral circulation may shorten the ischemic episode before injury becomes irreversible.
Plaque rupture exposes the necrotic core and tissue factor, whereas superficial erosion is characterized by thrombosis over an apparently intact cap with endothelial loss. The two pathways may produce the same clinical presentation. Conventional angiography shows the lumen and may not distinguish the substrate, whereas OCT can identify cap discontinuity, thrombus, and surface morphology with greater resolution; such characterization is primarily useful in selected cases and is not required for every unstable angina presentation.

Platelet microembolization may cause distal ischemia and small foci of injury. With high-sensitivity assays, many episodes that would previously have been classified as unstable angina are now reclassified as NSTEMI because acute myocardial injury associated with ischemia is detected; consequently, contemporary unstable angina is less frequent and represents a different population from that enrolled in historical trials using less sensitive biomarkers.
The distinction between reversible ischemia and necrosis is temporal as well as quantitative. A patient assessed very early may have a normal first troponin followed by a dynamic increase; diagnosis therefore requires serial measurements using algorithms validated for the assay. A single normal value cannot classify the episode as ischemia without necrosis if time from onset is short or clinical probability is high.

High-sensitivity cardiac troponin measures myocardial injury, not its mechanism. An elevated value may result from primary myocardial infarction, secondary myocardial infarction, myocarditis, heart failure, sepsis, tachyarrhythmia, or CKD. Conversely, a patient with transient atherothrombosis may have serially normal values. Interpretation must therefore combine absolute concentration, change over time, ECG, symptoms, and the clinical probability of ischemia.
In people with chronic CKD, the baseline value may remain above the 99th percentile; serial change and the clinical presentation are particularly important in this setting. Rapid algorithms remain useful, but a larger proportion of patients fall within the observation zone, requiring integrated judgment rather than a simple cutoff.

Emergency-department decision pathway, observation, and imaging selection

Initial assessment must immediately identify hemodynamic instability, persistent pain, life-threatening arrhythmias, acute heart failure, and dynamic ischemic changes; these features move the patient out of low-intensity pathways and require urgent cardiology management. In stable patients, history, ECG, and serial troponin instead permit progressive stratification that may avoid unnecessary admissions and angiography.
The ECG should be recorded promptly and repeated when symptoms recur. Dynamic ST depression or deep, symmetric T-wave inversion increases the probability of ischemia, but a normal ECG does not exclude it. Comparison with previous tracings is essential because chronic changes caused by hypertrophy, bundle branch block, or pacing may mimic or obscure ischemia.

Posterior or right-sided leads may be useful when the standard tracing is nondiagnostic but the distribution of symptoms or changes suggests a territory that is not adequately represented. The principle is not to increase the number of leads indiscriminately but to address a specific anatomical suspicion. An acute occlusion may sometimes present without classic elevation criteria on the standard 12-lead ECG.
Risk scores such as HEART or EDACS may support discharge pathways in selected patients, whereas GRACE is more focused on prognosis in ACS. No score supersedes a high-risk clinical feature. A patient with recurrent ischemic pain and dynamic ST changes does not become low risk merely because age and risk factors yield a favorable numerical score.

CCTA may be useful in low- or intermediate-risk patients when the diagnosis remains uncertain after ECG and troponin, particularly without extensive known coronary disease. Its strength lies in its high negative predictive value for significant coronary disease and its ability to document nonobstructive plaque. Severe calcification, tachycardia, arrhythmias, or previous stenting may limit quality.
Functional testing is appropriate when the principal question concerns inducible ischemia and anatomy does not require immediate invasive definition. Stress echocardiography, CMR, PET, and SPECT have different profiles of accuracy, availability, and radiation. Selection should depend on pretest probability, exercise capacity, and patient characteristics, not on a single algorithm for every chest-pain presentation.

Early discharge is safe only when event risk is sufficiently low and follow-up is reliable. Clear instructions must be provided regarding symptoms that require immediate return, treatment, and the timing of subsequent investigations. A formally correct pathway without continuity of care may fail in patients with limited access to healthcare.

Antithrombotic selection, bleeding risk, and complex populations

Aspirin is administered early when atherothrombotic ACS is likely and no contraindications exist. Addition of a P2Y12 inhibitor depends on the diagnosis, invasive strategy, and bleeding risk. Contemporary recommendations have reduced indiscriminate pretreatment before the anatomy is known in patients scheduled for early angiography because benefit may be offset by bleeding and the possibility that CABG will be required.
Parenteral anticoagulation during the acute phase reduces thrombus propagation but is not continued indefinitely without another indication, such as atrial fibrillation or an intracardiac thrombus. The choice among unfractionated heparin, enoxaparin, and other agents depends on the invasive strategy, kidney function, and context. Unnecessary duplication of anticoagulants increases bleeding without adding protection.

Bleeding risk should be assessed alongside ischemic risk. Advanced age, anemia, previous bleeding, CKD, malignancy, and the need for oral anticoagulation may modify the duration and intensity of DAPT. Abbreviated strategies or transition to P2Y12 monotherapy are appropriate in selected patients after PCI but must not be applied automatically to those with very high ischemic risk who tolerate therapy.
In patients with atrial fibrillation undergoing PCI, the combination of an oral anticoagulant and antiplatelet agents requires triple therapy for the shortest duration compatible with thrombotic risk, generally followed by an anticoagulant plus one antiplatelet agent and finally anticoagulation alone. The exact choice varies according to stent-thrombosis risk, bleeding, and the indication for anticoagulation.

Frail older patients often have less typical symptoms, CKD, and greater bleeding risk. Chronological age alone does not justify a conservative strategy, but the invasive decision must consider frailty, cognition, independence, and goals of care. Prevention of infarction must be balanced against the risks of delirium, functional loss, and procedural complications.
In women, the lower average probability of obstructive stenoses must not lead to underestimation of ischemic symptoms. SCAD, vasospasm, and microvascular dysfunction are relatively more frequent in some subgroups. If angiography shows no culprit lesion, the diagnostic pathway should continue when symptoms or ischemia persist rather than end with a nonspecific diagnosis of noncardiac pain.

In diabetes, atherothrombotic risk is high and neuropathy may attenuate pain. Dyspnea, weakness, or gastrointestinal symptoms may dominate the presentation. Acute glucose management should avoid both marked hyperglycemia and hypoglycemia, while long-term prevention should include drugs with cardiovascular benefit when indicated.
Management of ischemia without necrosis ultimately requires a discharge diagnosis consistent with the available data. If obstructive coronary disease has not been demonstrated, an initial suspicion of ACS must not automatically be converted into a definitive atherothrombotic diagnosis. Conversely, documenting a critical stenosis or culprit plaque carries prognostic significance even when troponin remains negative. Etiologic precision guides the duration of antithrombotic therapy, the need for revascularization, and secondary prevention.